

## Supplementary material

**Table S1.** Demographic, clinical and patient-centred measures differences between AQP4-IgG-positive and -negative patients.

	AQP4-IgG positive ( <i>n</i> = 27)	AQP4-IgG negative ( <i>n</i> = 13)	Corrected <i>p</i> -value
<b>Demographic and clinical data</b>			
Age (years)	46 (39.5 – 49)	42 (28 – 47)	0.464 <sup>b</sup>
Female, <i>n</i> (%)	25 (93)	9 (69)	0.428 <sup>a</sup>
Disease duration (years)	8.3 (6.3 – 17.6)	4.8 (1.6 – 10.1)	0.204 <sup>b</sup>
EDSS score (range)	2.0 (1.0 – 7.5)	2.0 (0 – 6.0)	0.942 <sup>b</sup>
Number of relapses	2.5 (1 – 4)	3 (2 – 3.5)	0.598 <sup>b</sup>
Current treatment, <i>n</i> (%)	27 (100)	9 (69)	0.120 <sup>a</sup>
Beck Depression Inventory-Fast Screen (BDI-FS)	3 (0 – 7.5)	3 (2 – 5)	0.570 <sup>b</sup>
Fatigue Impact Scale for Daily Use (D-FIS)	6 (2 – 18.5)	12 (3 – 17)	0.598 <sup>b</sup>
<b>Patient-centred measures</b>			
Physical MSIS-29v2	33 (23 – 48.5)	40 (28 – 59)	0.915 <sup>c</sup>
Psychological MSIS-29v2	18 (12.5 – 26)	25 (17 – 33)	0.620 <sup>c</sup>
Satisfaction with Life Scale (SWLS)	21 (18 – 28)	21 (18 – 24)	0.915 <sup>c</sup>
SymptoMScreen questionnaire (SyMS)	19 (7 – 29.5)	16 (10 – 32)	0.915 <sup>c</sup>
Stigma Scale for Chronic Illness (SSCI-8)	9 (8 – 13)	12 (9 – 15)	0.620 <sup>c</sup>
MOS Pain Effects Scale (PES)	14 (9 – 19.5)	17 (9 – 20)	0.914 <sup>c</sup>

The data represent the absolute numbers and proportions of qualitative data and the median and IQR for quantitative data, unless otherwise specified. AQP4-IgG: aquaporin-4 immunoglobulin G; EDSS: Expanded Disability Status Scale; MSIS-29v2: Multiple Sclerosis Impact Scale. One patient was excluded due to unknown serostatus.

<sup>a</sup>Chi-squared test; <sup>b</sup>Kruskal–Wallis test; <sup>c</sup>Age and sex-adjusted ANOVA and corrected by FDR adjustment.

**Table S2.** Demographic, clinical and patient-centred measures differences between CI and CP patients.

	CI patients ( <i>n</i> = 14)	CP patients ( <i>n</i> = 27)	Corrected <i>p</i> -value
<b>Demographic and clinical data</b>			
Age (years)	45 (41.5 - 52.8)	44 (28.5 - 45)	0.098 <sup>c</sup>
Female, women, <i>n</i> (%)	13 (93)	22 (81)	0.097 <sup>a</sup>
Disease duration	7.94 (2.38 - 11.9)	8.64 (5.03 - 15.6)	0.523 <sup>b</sup>
AQP4-IgG positive, <i>n</i> (%)	11 (79)	16 (59)	0.457 <sup>a</sup>
EDSS score (range)	3.0 (1.0 - 6.0)	2.0 (0 - 7.5)	0.267 <sup>b</sup>
Number of relapses	3 (3 - 4)	2 (1 - 3.75)	0.093 <sup>b</sup>
Current treatment, <i>n</i> (%)	13 (93)	24 (89)	0.999 <sup>a</sup>
Beck Depression Inventory-Fast Screen (BDI-FS)	4.5 (0.7 - 8)	2 (0.5 - 5)	0.248 <sup>b</sup>
Fatigue Impact Scale for Daily Use (D-FIS)	15.5 (5 - 19.8)	5 (2 -13)	0.109 <sup>b</sup>
<b>Patient-centred measures</b>			
Physical MSIS-29v2	46.5 (31.8 - 58.8)	32 (23 - 43.5)	0.055 <sup>d</sup>
Psychological MSIS-29v2	24.5 (17 - 32)	18 (11 - 26)	0.096 <sup>d</sup>
Satisfaction with Life Scale (SWLS)	18 (15 - 21)	22 (20 - 27.5)	0.043 <sup>d</sup>
SymptoMScreen questionnaire (SyMS)	26.5 (18.2 - 43.8)	11 (6 - 25.5)	0.043 <sup>d</sup>
Stigma Scale for Chronic Illness (SSCI-8)	13.5 (10 - 16)	9 (8 - 11)	0.043 <sup>d</sup>
MOS Pain Effects Scale (PES)	19 (12.5 - 21.8)	11 (8.5 - 19)	0.043 <sup>d</sup>

The data represent the absolute numbers and proportions of qualitative data and the median and IQR for quantitative data, unless otherwise specified. CP: cognitively preserved; CI: cognitive impairment; AQP4-IgG: aquaporin-4 immunoglobulin G; EDSS: Expanded Disability Status Scale; MSIS-29v2: MultipleSclerosis Impact Scale.

<sup>a</sup>Chi-squared test; <sup>b</sup>Kruskal-Wallis test; <sup>c</sup>Student's *t*-test; <sup>d</sup>Age and sex-adjusted ANOVA and corrected by FDR adjustment.